GlassScriptPhysician profile
Alexander Cubberley
NPI 1386174621
$22,838.65
in general payments reported to CMS, 2019-2025
25 companies · $4,510 in 2025
The $4,510 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $284 · 2021: $354 · 2022: $4,086 · 2023: $7,075 · 2024: $5,613 · 2025: $4,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,616 · Travel and Lodging: $6,970 · Grant: $2,000 · Education: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,615.81 |
| Travel and Lodging | $6,969.73 |
| Grant | $2,000.00 |
| Education | $611.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $8,881.09 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan, Azure Xt Dr Mri Surescan |
| Abbott Laboratories | $8,585.10 | 2022-2025 | Ensite Precision, Aveir, Ensite |
| Boston Scientific Corporation | $2,309.46 | 2022-2023 | |
| Impulse Dynamics (USA) INC. | $442.32 | 2024-2025 | Optimizer |
| Abiomed | $369.23 | 2022-2023 | Impella |
| Janssen Pharmaceuticals, INC | $326.90 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $211.50 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $189.38 | 2020-2022 | |
| Corindus INC. | $148.78 | 2019 | |
| Shockwave Medical, INC | $125.46 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Teleflex LLC | $125.25 | 2023 | Manta |
| Esperion Therapeutics, INC. | $124.97 | 2021 | |
| Abbvie INC. | $123.80 | 2019 | |
| Novo Nordisk INC | $123.48 | 2021 | |
| Philips North America LLC | $118.37 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $114.00 | 2019 | |
| Amarin Pharma, INC. | $105.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.39 | 2020 | |
| Amgen INC. | $80.45 | 2020 | |
| Novartis Pharmaceuticals Corporation | $70.72 | 2020-2025 | |
| Edwards Lifesciences Corporation | $55.40 | 2021 | |
| Scpharmaceuticals INC. | $49.38 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $23.40 | 2025 | Opsumit, Uptravi |
| Biosense Webster, INC. | $23.33 | 2022 | |
| Merck Sharp & Dohme LLC | $16.49 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Cubberley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.